The Value of ADAMTS13 in Predicting Clinical Outcomes in Patients With Acute Ischemic Stroke Receiving Thrombolysis
Conclusion: In our cohort, blood ADAMTS13 antigen level before rt-PA therapy could not be used as an independent biomarker in predicting clinical outcomes of AIS patients at 90 days.
Source: Frontiers in Neurology - Category: Neurology Source Type: research
More News: Atrial Fibrillation | Brain | China Health | Hemorrhagic Stroke | Ischemic Stroke | Neurology | Stroke | Thrombolytic Therapy | Thrombosis